Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.

GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient

A novel chemical method of labeling plasma proteins, compounds and substances containing proteins with the radionuclides of indium at physiologic pH 6-8 condition producing an efficiently labeled radioactive tracer material suitable for biomedical applications. These radiolabeled protein substances are not denatured by the labeling process but retain their native physiobiological properties. This novel labeling technique provides a simple and rapid means of labeling plasma proteins such as human serum albumin, transferrin, lactoferrin, fibrinogen, and immunoglobulin or antibodies with .sup.111 In or .sup.113m In for scintigraphic imaging which may allow visualization of thrombi, emboli, myocardial infarcts, infectious lesions, tumors or any vascular abnormalities in the body.

Novel physiologic chemical method of labeling protein substances with the radionuclides of indium

In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In accordance with yet another aspect of the present invention, magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a non-immunogenic, non-targeting macromolecule other than an antibody as contrast agents.

albumin/infark

Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient

Novel physiologic chemical method of labeling protein substances with the radionuclides of indium

Polydithicarbamate-containing non-targeting marcomolecules and the use thereof for therapeutic and diagnostic applications

Database tanaman obat terlengkap yang didukung oleh sains